EMA Authorised: Bilprevda (denosumab) — Sciencepharma Sp. z o.o

View source ↗

Summary

Authorised status for Bilprevda (denosumab) in the European Union for Giant Cell Tumor of Bone and Neoplasms of Bone Tissue.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Tumor of Bone
• Neoplasms Bone Tissue

Drugs mentioned

• BILPREVDA (DENOSUMAB)

Snippet

Status: Authorised. Therapeutic area: Giant Cell Tumor of Bone;Neoplasms, Bone Tissue. MAH: Sciencepharma Sp. z o.o. Decision date: 13/07/2026